Haloperidol (hydrochloride)

CAT:
804-HY-14538A-01
Size:
25 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Haloperidol (hydrochloride) - image 1

Haloperidol (hydrochloride)

  • Description:

    Haloperidol hydrochloride is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
  • UNSPSC:

    12352005
  • Hazard Statement:

    H301-H315-H317-H319-H335-H361
  • Target:

    Dopamine Receptor
  • Type:

    Reference compound
  • Related Pathways:

    GPCR/G Protein; Neuronal Signaling
  • Applications:

    Neuroscience-Neuromodulation
  • Field of Research:

    Neurological Disease; Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/Haloperidol-hydrochloride.html
  • Purity:

    99.5600
  • Solubility:

    DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
  • Smiles:

    ClC(C=C1)=CC=C1C2(O)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC2.Cl
  • Molecular Formula:

    C21H24Cl2FNO2
  • Molecular Weight:

    412.33
  • Precautions:

    P261-P264-P270-P271-P272-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
  • References & Citations:

    [1]Joy CB, et al. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2006 Oct 18; (4) :CD003082.|[2]Giannini AJ, et al. Acute ketamine intoxication treated by haloperidol: a preliminary study. Am J Ther. 2000 Nov;7 (6) :389-91.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    4°C (Powder, sealed storage, away from moisture)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    Launched
  • Isoform:

    D2 Receptor
  • Citation 01:

    Behav Brain Res. 2022 Mar 26:422:113759.|EMBO Rep. 2022 Feb 3;23 (3) :e53191.|ACS Omega. 2020 Nov 15;5 (46) :29935-29942.|ACS Omega. 2025 Oct 17;10 (42) :50208-50217.|Adv Sci (Weinh) . 2025 Sep;12 (33) :e02276.|BMC Endocr Disord. 2021 Nov 23;21 (1) :235.|Br J Pharmacol. 2021 Sep;178 (17) :3570-3586.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell. 2023 Nov 22;186 (24) :5347-5362.e24.|Clin Exp Pharmacol Physiol. 2021 Mar;48 (3) :370-380.|Environ Sci Technol. 2023 Sep 26;57 (38) :14162-14172.|Eur J Integr Med. 2021, 101322.|Eur J Pharmacol. 2023 Dec 15:961:176174.|Eur J Pharmacol. 2023 May 5:946:175647.|J Ethnopharmacol. 2021 Jun 12:273:113994.|Oncogenesis. 2025 Aug 21;14 (1) :31.|Phytomedicine. 2025 Jun:141:156707.|PLoS Negl Trop Dis. 2019 Aug 20;13 (8) :e0007681. |University of South Carolina. 2025.|University of Zurich. 2025.
  • CAS Number:

    1511-16-6